What Does Akathisia Feel Like? Inner Restlessness Explained

Akathisia feels like an unbearable internal compulsion to move, paired with a deep emotional unease that most people struggle to put into words. It is not simply fidgeting or having nervous energy. People who experience it describe a crawling tension inside their body, a relentless sense that sitting still is physically impossible, and an agitation that can feel indistinguishable from a panic attack. The condition most often appears as a side effect of medications that block dopamine receptors, including antipsychotic drugs and some common anti-nausea medications, and it remains one of the most misdiagnosed drug reactions in psychiatry.

What Patients Actually Describe

The word “akathisia” comes from the Greek for “inability to sit,” but that translation undersells what people go through. The experience is both physical and emotional. Patients report a gnawing inner tension, emotional unease, anxiety-like dread, a constant urge to shift position, and an inability to tolerate inactivity or rest.¹ The outward signs, like pacing, rocking, or repeatedly crossing and uncrossing legs, are just the visible tip. Underneath is a subjective state that researchers have long noted is hard for patients to articulate. One early clinical description put it bluntly: akathisia “refers not to any type or pattern of movement, but rather to a subjective need or desire to move.”²

Some people say it feels like their skin is crawling from the inside. Others compare it to the sensation you get when you desperately need to stretch a cramped muscle, except it never lets up and there is no stretch that relieves it. The legs are often the worst, but the restlessness can affect the entire body. Sitting in a chair feels like torture. Lying in bed at night becomes an exercise in futility. The emotional component is what makes it especially distressing: many patients say it is not just uncomfortable but terrifying, a feeling that something is deeply wrong but they cannot explain what.

Why Akathisia Gets Mistaken for Anxiety

One of the most consequential problems with akathisia is how easily it is confused with the psychiatric condition it often accompanies. A patient on an antipsychotic who suddenly becomes agitated, paces the hallway, and complains of vague unease can look exactly like someone whose underlying mental illness is worsening. Clinicians in that situation sometimes respond by increasing the dose of the very medication causing the problem, which makes the akathisia worse.

This misdiagnosis trap has been recognized for decades. Early researchers warned that akathisia “may appear like an anxiety state in which real anxiety can be neither recognized nor verbalized,” and that clues like pacing, insomnia, vague complaints about medication, and hyperactivity could all be subtle signs of akathisia rather than the patient’s psychiatric disorder.² The condition is also frequently unrecognized or misdiagnosed as agitation of psychiatric origin, which can lead to inappropriate dose increases that worsen the syndrome, or to the use of anti-anxiety drugs that merely mask symptoms without addressing the cause.¹

The distinction matters practically. If what you feel is anxiety from your psychiatric condition, increasing your antipsychotic dose or adding a benzodiazepine might help. If what you feel is akathisia caused by the antipsychotic, those same moves are likely to make things worse. Patients who suspect they are experiencing akathisia should tell their prescriber specifically about the physical restlessness and urge to move, because those features point toward akathisia more than generalized worry or dread alone.

Which Medications Trigger It

Akathisia is most commonly associated with antipsychotic medications, both the older first-generation drugs and the newer second-generation ones. There was an early hope that newer antipsychotics would spare patients from this side effect, but large studies have made clear that akathisia occurs with all commercially available second-generation antipsychotics, even if rates are lower than with older drugs.³ Research using large clinical databases confirms that while akathisia is less common with newer antipsychotics, it remains clinically significant and something every prescriber should watch for.⁴

But antipsychotics are far from the only culprits. Many people first encounter akathisia in an emergency room or after a routine prescription for nausea. A systematic review and meta-analysis looking at drugs commonly given for nausea and headache found that about one in six patients who received these medications developed akathisia. The rates varied by drug: prochlorperazine caused akathisia in roughly 27% of patients, haloperidol in about 20%, droperidol in around 13%, and metoclopramide in about 11%.⁵ Metoclopramide is especially worth knowing about because it is prescribed widely for stomach problems, and patients often do not realize it can cause neurological side effects.⁶

Selective serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, can also cause akathisia. The risk goes up when someone is taking more than one medication known to trigger it, when an SSRI dose has recently been increased, or when the patient has a history of previous akathisia episodes, a baseline psychiatric disorder, or a history of brain injury.⁷ SSRI-induced akathisia tends to be less recognized than the antipsychotic variety because antidepressants are not traditionally thought of as movement-disorder drugs, but the restlessness can be just as distressing.

What Happens in the Brain

The drugs that cause akathisia share a common thread: they interfere with dopamine signaling. In specific brain regions, blocking dopamine D2 receptors is what gives antipsychotics their therapeutic effect against psychosis. But in the striatum, a brain area involved in movement control, that same blockade can trigger movement-related side effects including akathisia. The risk rises sharply when more than about 80% of striatal D2 receptors are occupied by the drug.⁸

A PET imaging study demonstrated this directly. When researchers injected a D2 receptor-blocking compound into healthy volunteers and patients with schizophrenia, akathisia appeared in the majority of healthy subjects and about half of the patients, and the onset coincided with the moment of peak drug binding in the basal ganglia.⁹ A separate case report using PET scans on a patient with aripiprazole-induced akathisia found abnormally high metabolic activity in the putamen, a key part of the basal ganglia, further supporting the idea that this brain region is central to the problem.¹⁰

The serotonin system also plays a role, which is why SSRIs can trigger akathisia even though they do not directly block dopamine receptors. Serotonin and dopamine systems interact extensively, and boosting serotonin activity can indirectly suppress dopamine transmission in movement-related circuits. The full picture is still being worked out, but the dopamine-serotonin interplay explains why the list of offending drugs is broader than just traditional antipsychotics.

Acute, Chronic, and Tardive Forms

Akathisia is not one uniform condition. Clinicians classify it by when it shows up relative to medication use. Acute akathisia develops within days to weeks of starting a new drug or increasing a dose. Tardive akathisia appears after months or years of treatment and can persist even after the medication is stopped. Withdrawal akathisia emerges when a drug is reduced or discontinued. Chronic akathisia is a catch-all for cases that last beyond three months regardless of when they started.¹¹

The acute form is the most common and usually the most responsive to intervention, whether that means lowering the dose, switching to a different medication, or adding a treatment specifically for akathisia. Tardive akathisia is more stubborn and can sometimes become permanent, much like tardive dyskinesia. Withdrawal akathisia can blindside patients who are tapering off a medication and suddenly feel an intense restlessness they have never experienced before. Each type feels subjectively similar from the patient’s perspective, but the treatment approach and prognosis differ.

When Akathisia Becomes Dangerous

Akathisia is not just uncomfortable. It has serious clinical consequences. Research on patients with schizophrenia found that akathisia was associated with higher scores on measures of suicidality, depersonalization, and agitation.¹² The link to suicidality is especially concerning. The inner torment of severe akathisia can be so overwhelming that patients describe wanting to escape their own body. Some clinicians consider severe akathisia a psychiatric emergency for this reason.

The depersonalization connection is less well known but equally important. Patients sometimes report feeling detached from themselves or their surroundings, as though they are watching their own distress from a distance. This dissociative quality, layered on top of the physical restlessness and emotional anguish, can make the experience feel surreal and deeply frightening.

Akathisia also wrecks medication adherence. If a drug makes you feel like you are crawling out of your skin, you stop taking it. For someone with schizophrenia or bipolar disorder, stopping an antipsychotic abruptly can lead to relapse, hospitalization, or worse. Recognizing and treating akathisia early is one of the most practical things a clinician can do to keep patients on their medication regimens.

How Clinicians Measure It

Because akathisia is primarily a subjective experience, rating it formally requires both observation and conversation. The standard tool is the Barnes Akathisia Rating Scale, developed in the late 1980s and still used worldwide. It includes items for rating the visible restless movements, the patient’s own awareness of restlessness, the distress the patient associates with the experience, and a global severity score. The scale also includes diagnostic criteria that distinguish mild, moderate, and severe akathisia, as well as a category called pseudoakathisia, where the restless movements are present but the patient does not report the inner subjective distress.¹³ The scale has strong reliability between different raters and has been validated extensively.¹⁴

The pseudoakathisia category is worth pausing on. Some patients, particularly those with cognitive impairment or severe psychiatric illness, show the characteristic movements of akathisia (leg bouncing, shifting weight, inability to stay seated) but do not report inner distress. Whether these patients are truly not experiencing subjective restlessness or simply cannot articulate it remains debated. For practical purposes, clinicians treat pseudoakathisia with the same seriousness as the full syndrome.

Treatment Options That Have Evidence

The first line of treatment is usually the simplest: lower the dose of the offending drug or switch to one less likely to cause the problem. When that is not possible, because the patient needs that specific medication at that specific dose, several add-on treatments have evidence behind them.

A 2024 network meta-analysis evaluated ten different medications across fifteen clinical trials for antipsychotic-induced akathisia. The treatments that outperformed placebo were mirtazapine, biperiden, vitamin B6, trazodone, mianserin, and propranolol. Mirtazapine ranked first across all analyses.¹⁵ A separate trial found that about half of patients given low-dose mirtazapine met the response threshold within five days, compared to fewer than one in ten on placebo, and that mirtazapine worked comparably to propranolol.¹⁶

Some treatments that sound like they should work did not hold up. Clonazepam, cyproheptadine, zolmitriptan, and valproate all failed to beat placebo in the meta-analysis.¹⁵ This is useful to know because benzodiazepines like clonazepam are still commonly prescribed for akathisia in practice despite the weak evidence.

A practical mnemonic for clinicians, “B-CALM,” captures the evidence-based options: Beta-blockers (propranolol), Clonazepam, Anticholinergics, cLonidine, and Mirtazapine, though current evidence best supports propranolol and mirtazapine specifically.¹⁷ Vitamin B6, at high doses, is an interesting outlier: it showed meaningful benefit in the meta-analysis and has a favorable side-effect profile, though the evidence base is still small.

Why Some People Are More Vulnerable

Not everyone on the same drug at the same dose develops akathisia, and researchers have been looking for what makes certain people susceptible. Genetic variation appears to play a real role. A meta-analysis pooling data across dopaminergic, serotonergic, and metabolic gene pathways found that certain genetic variants were associated with roughly 70% higher odds of developing akathisia on antipsychotics.¹⁸

One specific genetic variant has gotten particular attention. Patients carrying a version of the DRD2/ANKK1 gene associated with lower dopamine D2 receptor density in the striatum developed akathisia on second-generation antipsychotics at more than double the rate of those without the variant: about 24% versus 11%.¹⁹ The logic tracks with what is known about D2 receptor occupancy: if you start with fewer receptors, a standard drug dose blocks a higher percentage of them, pushing you past the occupancy threshold where akathisia becomes likely.⁸

Beyond genetics, other known risk factors include higher medication doses, rapid dose escalation, a prior history of akathisia, iron deficiency (which affects dopamine metabolism), and concurrent use of multiple drugs that act on dopamine or serotonin systems.⁷ Iron status is an underappreciated factor. Low serum ferritin has been linked to akathisia risk in several studies, likely because iron is a cofactor for dopamine synthesis. Some clinicians check ferritin levels in patients with persistent akathisia, and correction of iron deficiency has been reported to help in individual cases, though large controlled trials are lacking.

Akathisia Before the Drug Era

Although the word akathisia is now almost synonymous with medication side effects, the concept actually predates antipsychotic drugs. The term was first used in the early twentieth century to describe a restless inability to sit still in patients with neurological conditions like Parkinson’s disease and post-encephalitic syndromes. It was only after antipsychotic medications came into widespread use in the 1950s that drug-induced akathisia became the dominant meaning.²⁰

That earlier history matters because akathisia is not exclusively a drug side effect. People with Parkinson’s disease, those recovering from strokes affecting the basal ganglia, and patients with certain autoimmune neurological conditions can develop akathisia with no medication trigger at all. The common denominator is disruption of the dopamine system in the movement-control circuits of the brain, whether caused by a pill or by disease. Understanding this broader context can prevent the mistake of assuming a patient’s restlessness must be drug-related when it might instead be a neurological symptom that needs its own workup.